Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Comment by ohbehaveon Jun 10, 2019 1:58pm
59 Views
Post# 29812484

RE:RE:RE:stuck

RE:RE:RE:stuckIt would seem obvious to most investors (but perhaps not "Theconsortman") that the junior world is a high risk (and hopefully at some point a high reward) place to be invested these days and not the place for everyone. As I've stated before, under the circumstances, I would argue that PLX has done a decent job of not only developing and advancing the companies prospects but also of managing thier debt and financings and I certainly dont think PLX is unique in the challenges they are facing. This company seems to be doing what they have to do to get an exciting new discovery on production and position themselves to develop this play and the other plays they've internally generated. In a normal market PLX would have $$ pouring into every financing but most recognize that this is not a normal market. You either accept the risk and bet on the company's ability to execute and on future improvement in market conditions or you shouldnt be invested in Junior O&G. If "Theconsortman" has a better financing solution for the Junior O&G sector I'm certain the managment of PLX (and every other managment team in Calgary) would love to be enlightened with his wisdom. "Theconsortman" ... if you have something constructive to contribute then please do so but if you simply have a grudge aginst PLX then sell your stock (if you actually own any) and take the constant bashing elswhere.

Based on the PR test rates, PLX share of production from only this first Rex HZ well (on production now?) stands to more than double the company's current net oil production and importantly their cash flow with a material inventory of development locations. The recent farmout deal gives the company two additional wells into the play at zero cost and they had to give up something to get that. The "shares for payables" deal keeps them essentially debt free. It's always preferable to see financings done at ever higher share prices but again this is not a normal market and given some positive results from this first well investors that have shown some patience and understanding should ultimately be rewarded.
<< Previous
Bullboard Posts
Next >>